1-(2-Chlorophenyl)cyclobutanecarbonitrile – (28049-59-4)

suxibuzone, 27470-51-5, Calibene, Suxibuzona, Flogos, Suxibuzonum, Solurol, Flamilon, Aflogan, Alfide, 4-Hydroxymethylbutazolidine hemisuccinate, AE-17, Suxibuzonum [INN-Latin], Suxibuzona [INN-Spanish], 4-((4-Butyl-3, 5-dioxo-1, 2-diphenylpyrazolidin-4-yl)methoxy)-4-oxobutanoic acid, CHEBI:32173, 4-Butyl-4-hydroxymethyl-1, 2-diphenyl-3, 5-pyrazolidinedione hydrogen succinate, AE 17, 4-[(4-butyl-3, 5-dioxo-1, 2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid, EINECS 248-477-6, 86TDZ5WP2B, Suxibuzone [INN:BAN:JAN], NSC-757866, BRN 0904563, DTXSID6021296, SUXIBUZONE [INN], SUXIBUZONE [JAN], 4-BUTYL-4-[HYDROXYMETHYL]-1, 2-DIPHENYL-3, 5-PYRAZOLIDINEDIONE HYDROGEN SUCCINATE [ESTER], SUXIBUZONE [MART.], SUXIBUZONE [WHO-DD], 4-Butyl-4-(hydroxymethyl)-1, 2-diphenyl-3, 5-pyrazolidinedione hydrogen succinate (ester), Succinic acid, monoester with 4-butyl-4-(hydroxymethyl)-1, 2-diphenyl-3, 5-pyrazolidinedione, DTXCID601296, SUXIBUZONE [EP IMPURITY], SUXIBUZONE [EP MONOGRAPH], 3-((4-Butyl-3, 5-dioxo-1, 2-diphenyl-4-pyrazolidinyl)methoxycarbonyl)propionsaeure, 4-Butyl-4-(beta-carboxypropionyl-oxymethyl)-1, 2-diphenyl-3, 5-pyrazolidinedione, 3, 5-Pyrazolidinedione, 4-butyl-4-(hydroxymethyl)-1, 2-diphenyl-, hydrogen succinate (ester), NSC 757866, NCGC00016799-01, CAS-27470-51-5, Suxibuzonum (INN-Latin), Suxibuzona (INN-Spanish), SUXIBUZONE (MART.), Butanedioic acid, mono((4-butyl-3, 5-dioxo-1, 2-diphenyl-4-pyrazolidinyl)methyl) ester, SUXIBUZONE (EP IMPURITY), SUXIBUZONE (EP MONOGRAPH), Butanedioic acid, mono[(4-butyl-3, 5-dioxo-1, 2-diphenyl-4-pyrazolidinyl)methyl] ester, SR-01000841241, UNII-86TDZ5WP2B, Suxibuzon, Suxibuzone 4-[(4-Butyl-3, 5-dioxo-1, 2-diphenylpyrazolidin-4-yl)methoxy]-4-oxobutanoic acid, Prestwick_113, Suxibuzone (Standard), Spectrum_000321, Suxibuzone (JAN/INN), Prestwick0_000658, Prestwick1_000658, Prestwick2_000658, Prestwick3_000658, Spectrum2_000966, Spectrum3_000664, Spectrum4_000433, Spectrum5_001113, Epitope ID:124941, 1, 2-Diphenyl-4-n-butyl-4-hydroxymethyl-3, 5-dioxopyrazolidine Hemisuccinate, 4-butyl-4-(beta-carboxypropionyloxymethyl)-1, 2-diphenyl-3, 5-pyrazolidinedione, SCHEMBL25810, BSPBio_000695, BSPBio_002327, KBioGR_000786, KBioSS_000801, MLS002153938, DivK1c_000171, SPECTRUM1501157, SPBio_000971, SPBio_002616, BPBio1_000765, CHEMBL1414320, HMS500I13, HY-B1079R, KBio1_000171, KBio2_000801, KBio2_003369, KBio2_005937, KBio3_001547, BRD5826, M02AA22, NINDS_000171, HMS1570C17, HMS1923I17, HMS2097C17, HMS2232E17, HMS3371A12, HMS3714C17, Pharmakon1600-01501157, BRD-5826, HY-B1079, Tox21_110615, Tox21_202352, Tox21_302778, CCG-40180, NSC757866, AKOS024374988, Tox21_110615_1, CS-4635, DB13232, 4-{[(4-butyl-3, 5-dioxo-1, 2-diphenylpyrazolidin-4-yl)methyl]oxy}-4-oxobutanoic acid, IDI1_000171, NCGC00016799-02, NCGC00016799-03, NCGC00016799-04, NCGC00016799-05, NCGC00016799-06, NCGC00016799-08, NCGC00095261-01, NCGC00095261-02, NCGC00095261-03, NCGC00095261-04, NCGC00256470-01, NCGC00259901-01, MS-27855, SMR001233279, SBI-0051667.P002, DB-047228, AB00052229, NS00008152, D01289, F85232, AB00052229_08, AB00052229_09, Q7650623, SR-01000841241-2, SR-01000841241-3, BRD-K78815826-001-05-4, BRD-K78815826-001-08-8, BRD-K78815826-001-13-8, BRD-K78815826-001-14-6, Suxibuzone, European Pharmacopoeia (EP) Reference Standard, 4-[(4-Butyl-3, 5-dioxo-1, 2-diphenyl-4-pyrazolidinyl)methoxy]-4-oxobutanoic acid, 4-Butyl-4-(.beta.-carboxypropionyl-oxymethyl)-1, 2-diphenyl-3, 5-pyrazolidinedione, 248-477-6, Butanedioic acid, mono((4-butyl-3, 5-dioxo-1, 2-diphenyl-4-pyrazolidinyl)methyl) ester (9CI)